Hikal (HIKAL) Fundamentals 2026 — Revenue Analysis | SniperIQ
Hikal (HIKAL) is a India-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ₹2,634 Crore, trading at ₹213.65 on the NSE. This SniperIQ fundamentals page covers Hikal's valuation, profitability (net margin -2.9%), revenue (₹1,713 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hikal's market cap?
Hikal (HIKAL) has a market capitalization of approximately ₹2,634 Crore, trading at ₹213.65 on the NSE. Market cap moves with the live share price.
What is Hikal's P/E ratio?
Hikal's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hikal?
Hikal runs a net profit margin of -2.9%, a gross margin of 42.2%, and an operating margin of 3.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hikal generate?
Hikal reported revenue of ₹1,713 Crore for fiscal year 2026, with net income of -₹49 Crore and earnings per share (EPS) of -3.96. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hikal pay a dividend?
Hikal offers a trailing dividend yield of about 0.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Hikal financially healthy?
Hikal carries a debt-to-equity ratio of 0.57x and a current ratio of 1.30x, with a market beta of 1.69. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hikal a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hikal (HIKAL) the key facts are: market cap ₹2,634 Crore, revenue ₹1,713 Crore, 52-week range 146.25-343.85. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hikal's full fundamentals live
Get Hikal's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.